CD4 and melanoma: To investigate the relevance of circulating DC subsets (cDC1s, cDC2s and pDCs) and effector cells (γδ2+T, γδ2–T, iNKT, CD4+ T, CD8+ T, NKbright and NKdim cells) in the response to anti-PD1, we first assessed the frequencies of these immune cells in the blood of melanoma patients before and during the treatment (T0, T3/6, T12, T24).